Vicarious Surgical has named Stephen From as its new chief executive officer (CEO) and member of the company’s board of directors, effective August 7, 2025.

From boasts more than two decades of leadership experience in the medical device industry. He was most recently CEO of Aruna Bio, guiding direction and clinical advancement of its neural exosome platform.

“It has been an incredible journey to lead Vicarious Surgical from its inception through pre-clinical testing, and I’m proud of all we’ve accomplished to date. As I transition into the role of President, I’m excited to welcome Stephen as our new CEO,” said Adam Sachs, current CEO, Co-Founder, and Board member. “I believe his leadership and experience are exactly what we need at this pivotal stage, and I look forward to working closely with him to advance our mission of transforming surgical care through innovative robotics.”

From October 2005 through February 2021, From was president and CEO of the company, and from February 2021 through January 2022 was executive chairman of Kiora Pharmaceuticals, formerly known as EyeGate Pharmaceuticals.

Before EyeGate he was chief financial officer (CFO) of Centelion, then a biotech subsidiary of Sanofi-Aventis, and spent several years in investment banking. There he focused on the life sciences sector at Bank of America Securities and Robertson Stephens.

“I am honored to join the Vicarious Surgical team at this pivotal time in its evolution. The company’s technology offers a significant advancement from today’s surgical approaches with the potential to transform modern surgery and improve outcomes for patients worldwide,” said From. “I look forward to working alongside this talented team and Board to advance our strategic priorities and deliver on the promise of this innovative platform.”

Earlier this year, the company announced that its president Randy Clark will transition to board member, effective April 25.